Results 11 to 20 of about 4,412 (151)

The Efficacy and Safety of Heterologous Immunization with Pfizer-BioNTech (Pfizer) to Individuals Who Have Completed A Primary Vaccination Schedule with Sinopharm (BBibp-CorV) [PDF]

Journal of Pure and Applied Microbiology, 2023
The aim of this study was to examine the effectiveness and potential adverse reactions when providing a different Pfizer-BioNTech booster shot to 235 volunteers who had previously received the BBIBP-CorV Sinopharm primary vaccination series.
Nawfal R. Hussein, Warveen L. Abdulkareem, Narin A. Rasheed, Mohammed Rashid Ameen   +3 more
doaj   +3 more sources

A real-world study of BBIBP-CorV vaccine effectiveness in a Sri Lanka rural province [PDF]

Heliyon
Objective: Real-world studies assessing the effectiveness of the BBIBP-CorV vaccine in low and middle-income countries are limited. We evaluated the BBIBP-CorV vaccine's effectiveness in reducing COVID-19 symptomatic disease, hospitalisation, severe ...
Lanka Wijekoon, Nuwan Wickramasinghe, Thilina Rathnasekara, Thejana Somathilake, Chamara Sarathchandra, Hemal Senanayake, Prasanna Weerawansa, Ranjan Ganegama, Yuntao Zhang, Yunkai Yang, Rui Ma, Yaowen Zhang, Deying Xie, Zhaofeng Li, Xiaodan Liu, Shouyi Qin, Sisira Siribaddana   +16 more
doaj   +2 more sources

Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study [PDF]

BMC Public Health
Background Given the limited evidence on the side effects of AZD1222 booster in individuals previously vaccinated with Sinopharm BBIBP-CorV, we conducted a cohort event monitoring study to capture adverse events in those receiving AZD1222 booster doses ...
Shahin Soltani, Mehdi Moradinazar, Behzad Karamimatin, Mohammad Mehdi Gouya, Sayed Mohsen Zahraei, Ghobad Moradi, Omid Chehri, Moslem Soofi, Fatemeh Khosravi Shadmani, Mahsa Kalantari, Farid Najafi   +10 more
doaj   +2 more sources

Clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among 572 fully vaccinated (BBIBP-CorV) hospitalized patients [PDF]

Heliyon, 2023
Background: Breakthrough infections have been widely reported in vaccinated individuals. However, the clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among fully vaccinated (BBIBP-CorV) hospitalized patients ...
Yihuang Liu, Peilin Liu, Yuming Sun, Guangtong Deng   +3 more
doaj   +2 more sources

Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial [PDF]

BMC Medicine
Background The immunity induced by primary vaccination is effective against COVID-19; however, booster vaccines are needed to maintain vaccine-induced immunity and improve protection against emerging variants.
Saeed Erfanpoor, Seyed Reza Banihashemi, Ladan Mokhbaeralsafa, Saeed Kalantari, Ali Es-haghi, Mojtaba Nofeli, Ali Rezaei Mokarram, Fariba Sadeghi, Monireh Hajimoradi, Seyad Hossein Razaz, Maryam Taghdiri, Mohsen Lotfi, Akbar Khorasani, Akram Ansarifar, Safdar Masoumi, Arash Mohazzab, Sara Filsoof, Vahideh Mohseni, Masoumeh Shahsavan, Niloufar Gharavi, Seyed Amin Setarehdan, Mohammad Hasan Rabiee, Mohammad Hossein Fallah Mehrabadi, Masoud Solaymani-Dodaran   +23 more
doaj   +2 more sources

BBIBP-CorV [PDF]

Reactions Weekly, 2022
  +14 more sources

Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm [PDF]

Iranian Journal of Immunology, 2022
Background: Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2).Objectives: To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the ...
Enayat Anvari, Atefe Talepoor, Mahsa Eshkevar Vakili, Narges Karimi, MohammadReza Ataollahi, Gelareh Najafi, Dieter Kabalitz, Iraj Ahmadi, Kurosh Kalantar   +8 more
doaj   +1 more source

Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.

PLoS ONE, 2022
BackgroundMass vaccination is the key element in controlling current COVID-19 pandemic. Studies comparing immunogenicity of different COVID-19 vaccines are largely lacking. We aimed at measuring anti-S antibody (Ab) levels in individuals fully vaccinated
Vladimir Petrović, Vladimir Vuković, Aleksandra Patić, Miloš Marković, Mioljub Ristić   +4 more
doaj   +1 more source

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. [PDF]

, 2022
NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen.
Cong, Xiangfeng, Du, Li, ElDein, Mohamed, Eltantawy, Islam, Gao, Xue, Hou, Jun, Hussein, Salah, Jiang, Zhiwei, Kaabi, Nawal, Kang, Yun, Lei, Wenwen, Lei, Ze, Li, Meng, Li, Qi, Liang, Yu, Liu, Dan, Mahmoud, Sally, Mao, Xiao, Mekki, Hanadi, Qu, Chang, Qu, Liang, Shao, Shuai, Su, Ji, Tan, Yao, Wang, Hui, Wang, Zhao, Wu, Guizhen, Xiao, Peng, Xu, Ke, Yang, Mengjie, Yang, Sen, Yang, Tian, Yang, Xiao, Yang, Yun, Yin, Jin, Zaher, Walid, Zhang, Jin, Zhang, Jing, Zhang, Jing, Zhang, Xue, Zhang, Yun   +40 more
core   +1 more source

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

Vaccines, 2022
In the present study, antibody and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines were compared 6 months after the two-dose immunization of healthy individuals.
Zsolt Matula, Márton Gönczi, Gabriella Bekő, Béla Kádár, Éva Ajzner, Ferenc Uher, István Vályi-Nagy   +6 more
doaj   +1 more source